

FINAL EXAM
DECEMBER 2016

NATIONAL BOARD OF EXAMINATIONS

HEMATOLOGY**PAPER – III**

HEMAT/D/16/48/III

Time : 3 hours

Max. Marks : 100

Important instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Clinical and laboratory diagnosis of anti-phospholipid antibody syndrome (APLA). 5+5
b) How do you manage a case of recurrent pregnancy loss in a case of APLA?
2. In deep vein thrombosis/Pulmonary thromboembolism: 3+3+2+2
a) How do you manage initially?
b) How do you do transition from initial treatment?
c) How do you select anti-coagulants?
d) How do you monitor and for how long?
3. a) Enumerate anti-platelet drugs. 2+4+4
b) Advantages of newer anti-platelet drugs.
c) Role of platelet transfusion in anti-platelet associated bleeding.
4. Discrepancies between genotypic and phenotypic expressions in: 5+5
a) Hemoglobinopathies
b) Bleeding disorders.
5. a) Classify myeloid neoplasms. 4+3+3
b) Mention the mutations in polycythemia vera, essential thrombocythemia and myelofibrosis
c) What is their potential significance?
6. a) Name thrombopoietic agents. 2+3+5
b) What are their side effects?
c) What is their role in ITP?
7. In acute lymphatic leukemia. 4+2+4
a) Event free survival in children and adults.
b) Treatment related mortality.
c) Long term effects

P.T.O.

FINAL EXAM
DECEMBER 2016

NATIONAL BOARD OF EXAMINATIONS

HEMATOLOGY**PAPER – III**

8. a) Enumerate the thalassemic syndromes. 3+5+2
b) Importance of screening for thalassemia in antenatal mothers.
c) What are the antenatal diagnostic tests available in different trimesters of pregnancy?
9. a) Classify myelodysplastic syndromes. 3+(2+2+3)
b) Clinical features, pathological factors and differential diagnosis of myelodysplastic syndromes.
10. Newer drugs/products in malignant hematology. 10

www.FirstRanker.com